Avalanche Biotechnologies, Inc.

Founded in 2006, Avalanche is a publicly traded (AAVL) biotechnology company that develops technologies and products for sustained delivery of therapeutic proteins to the eye to treat wet age-related macular degeneration (AMD), as well as other ophthalmologic disorders, such as diabetic retinopathy, retinal degeneration, and glaucoma. Using a next generation gene therapy platform, the Ocular BioFactory™, the Company is developing products designed to provide long-term benefit, or a functional CURE, by inducing a sustained expression of a therapeutic protein with a one-time administration in the eye. Avalanche is a biopharmaceutical company committed to improving or preserving the sight of people with serious eye diseases with an unmet medical need. Using a next generation gene therapy platform, the Ocular BioFactory™, the Company is developing product candidates designed to provide long-term efficacy by inducing a sustained expression of a therapeutic protein with the potential for a one-time administration in the eye.